Genzyme and PTC Therapeutics have entered an exclusive global collaboration to develop and commercialize PTC124, PTC’s late-stage oral therapy for the treatment of genetic disorders due to nonsense mutations.     Under the terms of the agreement, PTC will commercialize the drug in the U.S. and Canada, and Genzyme will commercialize the treatment in all other countries. Genzyme will make an up-front payment of $100 million, plus potential milestone and royalty payments. PTC will be finan...